| __timestamp | TG Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 24518692 | 612613000000 |
| Thursday, January 1, 2015 | 19886580 | 650773000000 |
| Friday, January 1, 2016 | 12631689 | 619061000000 |
| Sunday, January 1, 2017 | 21977998 | 628106000000 |
| Monday, January 1, 2018 | 20759000 | 717599000000 |
| Tuesday, January 1, 2019 | 20838000 | 964737000000 |
| Wednesday, January 1, 2020 | 121812000 | 875663000000 |
| Friday, January 1, 2021 | 152137000 | 886361000000 |
| Saturday, January 1, 2022 | 83231000 | 997309000000 |
| Sunday, January 1, 2023 | 122706000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unlocking the unknown
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc. have showcased contrasting SG&A spending patterns. Takeda, a global leader, consistently allocated substantial resources, with a peak in 2023 reaching over 1 trillion yen, reflecting its expansive operations and market reach. In contrast, TG Therapeutics, a smaller biotech firm, demonstrated a more volatile pattern, with a significant spike in 2020, where SG&A expenses surged by over 500% compared to 2014. This divergence highlights the strategic priorities of each company: Takeda's focus on maintaining global operations versus TG Therapeutics' agile approach to market challenges. Notably, data for TG Therapeutics in 2024 is missing, indicating potential shifts in strategy or reporting.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alkermes plc and TG Therapeutics, Inc.
Opthea Limited vs TG Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and Perrigo Company plc
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Dynavax Technologies Corporation Trends and Insights